Study to Assess the Effect of Co‑administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran etexilate in Healthy Postmenopausal Female Volunteers

Exclusion Criteria

• - History of any clinically significant disease or disorder as described by the Investigator.
• - History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• - Use of systemic estrogen-containing hormone replacement therapy within 6 months prior to first dose in the study.
• - Have taken any proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, pantoprazole, etc.) within 14 days of beginning study treatment (ie, first administration of omeprazole in Arm A.
• - Have taken any drug with enzyme-inducing properties such as St John’s Wort within 3 weeks of screening.
• - Presence of any contraindication to the probe substrates omeprazole, midazolam, dabigatran or celecoxib per the United States Package Insert.
• - Any of the following signs or confirmation of COVID-19 infection:
• - Subject has a positive RT-PCR test for SARS-CoV-2 prior to randomization.
• - Clinical signs and symptoms consistent with COVID-19 (eg, fever, dry cough, dyspnea, sore throat, fatigue) or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or at randomization.
• - Subject has been previously hospitalized with COVID-19 infection within the last 12 months.